Cargando…
Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAF(V600)- mutated melanoma (BRIM7)
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4126212/ http://dx.doi.org/10.1186/1479-5876-12-S1-O7 |
| _version_ | 1782329882792951808 |
|---|---|
| author | Puzanov, Igor McArthur, Grant Gonzalez, Rene Pavlick, Anna Hamid, Omid Gajewski, Thomas F Yin, Ming Fredrickson, Jill Choong, Nicholas Ribas, Antoni |
| author_facet | Puzanov, Igor McArthur, Grant Gonzalez, Rene Pavlick, Anna Hamid, Omid Gajewski, Thomas F Yin, Ming Fredrickson, Jill Choong, Nicholas Ribas, Antoni |
| author_sort | Puzanov, Igor |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4126212 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-41262122014-08-11 Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAF(V600)- mutated melanoma (BRIM7) Puzanov, Igor McArthur, Grant Gonzalez, Rene Pavlick, Anna Hamid, Omid Gajewski, Thomas F Yin, Ming Fredrickson, Jill Choong, Nicholas Ribas, Antoni J Transl Med Oral Presentation BioMed Central 2014-05-06 /pmc/articles/PMC4126212/ http://dx.doi.org/10.1186/1479-5876-12-S1-O7 Text en Copyright © 2014 Puzanov et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Oral Presentation Puzanov, Igor McArthur, Grant Gonzalez, Rene Pavlick, Anna Hamid, Omid Gajewski, Thomas F Yin, Ming Fredrickson, Jill Choong, Nicholas Ribas, Antoni Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAF(V600)- mutated melanoma (BRIM7) |
| title | Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAF(V600)- mutated melanoma (BRIM7) |
| title_full | Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAF(V600)- mutated melanoma (BRIM7) |
| title_fullStr | Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAF(V600)- mutated melanoma (BRIM7) |
| title_full_unstemmed | Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAF(V600)- mutated melanoma (BRIM7) |
| title_short | Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAF(V600)- mutated melanoma (BRIM7) |
| title_sort | updated results and correlative fdg-pet analysis of a phase ib study of vemurafenib and cobimetinib (mek inhibitor [gdc-0973]), in advanced braf(v600)- mutated melanoma (brim7) |
| topic | Oral Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4126212/ http://dx.doi.org/10.1186/1479-5876-12-S1-O7 |
| work_keys_str_mv | AT puzanovigor updatedresultsandcorrelativefdgpetanalysisofaphaseibstudyofvemurafenibandcobimetinibmekinhibitorgdc0973inadvancedbrafv600mutatedmelanomabrim7 AT mcarthurgrant updatedresultsandcorrelativefdgpetanalysisofaphaseibstudyofvemurafenibandcobimetinibmekinhibitorgdc0973inadvancedbrafv600mutatedmelanomabrim7 AT gonzalezrene updatedresultsandcorrelativefdgpetanalysisofaphaseibstudyofvemurafenibandcobimetinibmekinhibitorgdc0973inadvancedbrafv600mutatedmelanomabrim7 AT pavlickanna updatedresultsandcorrelativefdgpetanalysisofaphaseibstudyofvemurafenibandcobimetinibmekinhibitorgdc0973inadvancedbrafv600mutatedmelanomabrim7 AT hamidomid updatedresultsandcorrelativefdgpetanalysisofaphaseibstudyofvemurafenibandcobimetinibmekinhibitorgdc0973inadvancedbrafv600mutatedmelanomabrim7 AT gajewskithomasf updatedresultsandcorrelativefdgpetanalysisofaphaseibstudyofvemurafenibandcobimetinibmekinhibitorgdc0973inadvancedbrafv600mutatedmelanomabrim7 AT yinming updatedresultsandcorrelativefdgpetanalysisofaphaseibstudyofvemurafenibandcobimetinibmekinhibitorgdc0973inadvancedbrafv600mutatedmelanomabrim7 AT fredricksonjill updatedresultsandcorrelativefdgpetanalysisofaphaseibstudyofvemurafenibandcobimetinibmekinhibitorgdc0973inadvancedbrafv600mutatedmelanomabrim7 AT choongnicholas updatedresultsandcorrelativefdgpetanalysisofaphaseibstudyofvemurafenibandcobimetinibmekinhibitorgdc0973inadvancedbrafv600mutatedmelanomabrim7 AT ribasantoni updatedresultsandcorrelativefdgpetanalysisofaphaseibstudyofvemurafenibandcobimetinibmekinhibitorgdc0973inadvancedbrafv600mutatedmelanomabrim7 |